Targeted blocking of LINC01123 may improve anti-tumor immunity; reverse CD8+T-cell dysfunction; and ultimately, limit tumor proliferation, metastasis, and recurrence; and improve the prognosis of patients. Here, CD8A is linked to neoplasm.